Russia, Chinese Firms to Collaborate on Producing Sputnik V Vaccine in China

Hualan Biological Bacterin, a leading vaccine manufacturer in China, has agreed to produce more than 100 million annual doses of Russia’s Sputnik V vaccine for distribution in the country.

The controversial two-dose vaccine, which was initially authorized in Russia ahead of phase 3 trials, has since shown 91.6 percent efficacy against COVID-19 infection, based on peer-reviewed data.

The Russian Direct Investment Fund (RDIF), which funded Sputnik V’s development, said the vaccine has now been authorized in more than 60 countries.